This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ESPR - Esperion settles patent dispute with Dr. Reddy's over cholesterol drugs

ESPR - Esperion settles patent dispute with Dr. Reddy's over cholesterol drugs

October, 03 2025 10:49 AM Esperion Therapeutics Inc.

2025-10-03 10:49:58 ET

More on Esperion Therapeutics, Dr. Reddy's

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
SA Asks: How could higher India tariffs impact drug stocks?
Esperion rises after revenue beat, Q1 profitability expectation

For further details see:

Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs

Stock Information

Company Name:	Esperion Therapeutics Inc.
Stock Symbol:	ESPR
Market:	NASDAQ
Website:	esperion.com

Get ESPR Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.